loading
Precedente Chiudi:
$8.35
Aprire:
$8.38
Volume 24 ore:
342.35K
Relative Volume:
0.08
Capitalizzazione di mercato:
$1.76B
Reddito:
$503.49M
Utile/perdita netta:
$-53.47M
Rapporto P/E:
-32.42
EPS:
-0.26
Flusso di cassa netto:
$-26.89M
1 W Prestazione:
+6.18%
1M Prestazione:
-3.97%
6M Prestazione:
-3.20%
1 anno Prestazione:
+5.91%
Intervallo 1D:
Value
$8.30
$8.45
Intervallo di 1 settimana:
Value
$8.095
$9.14
Portata 52W:
Value
$6.015
$11.31

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name
Nome
Biocryst Pharmaceuticals Inc
Name
Telefono
919-859-1302
Name
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
Dipendente
580
Name
Cinguettio
@biocrystpharma
Name
Prossima data di guadagno
2025-02-24
Name
Ultimi documenti SEC
Name
BCRX's Discussions on Twitter

Confronta BCRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
BCRX
Biocryst Pharmaceuticals Inc
8.425 1.81B 503.49M -53.47M -26.89M -0.26
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
146.80 64.93B 9.39B 2.61B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.43 45.07B 29.98B 958.27M 5.31B 0.2964
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.485 41.53B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.16 18.37B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
302.24 13.68B 2.99B 1.21B 1.13B 25.06

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-29 Iniziato Cantor Fitzgerald Overweight
2025-02-25 Iniziato Wedbush Outperform
2023-11-20 Ripresa JP Morgan Overweight
2023-09-18 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-08-04 Aggiornamento Jefferies Hold → Buy
2023-07-13 Aggiornamento BofA Securities Neutral → Buy
2023-02-22 Aggiornamento Needham Hold → Buy
2022-11-02 Aggiornamento Evercore ISI In-line → Outperform
2022-08-05 Downgrade Evercore ISI Outperform → In-line
2022-08-05 Downgrade Oppenheimer Outperform → Perform
2022-04-18 Downgrade Barclays Overweight → Equal Weight
2022-04-11 Downgrade BofA Securities Buy → Neutral
2021-12-10 Iniziato Oppenheimer Outperform
2021-08-06 Downgrade Jefferies Buy → Hold
2021-08-03 Iniziato Cantor Fitzgerald Overweight
2021-03-01 Iniziato Cowen Outperform
2020-09-29 Ripresa JP Morgan Overweight
2020-06-17 Iniziato BTIG Research Neutral
2020-05-05 Aggiornamento Barclays Equal Weight → Overweight
2019-11-15 Aggiornamento BofA/Merrill Neutral → Buy
2019-05-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
2018-11-16 Ripresa Piper Jaffray Overweight
2018-08-08 Ripresa JP Morgan Overweight
2018-07-17 Aggiornamento BofA/Merrill Underperform → Neutral
2018-06-22 Iniziato Seaport Global Securities Neutral
2018-01-02 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2017-12-20 Iniziato Barclays Equal Weight
2017-09-15 Iniziato RBC Capital Mkts Sector Perform
2017-09-06 Aggiornamento JP Morgan Neutral → Overweight
2017-09-06 Aggiornamento Jefferies Hold → Buy
2017-02-16 Iniziato Ladenburg Thalmann Buy
2016-08-12 Aggiornamento Piper Jaffray Neutral → Overweight
2016-08-04 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 Reiterato FBR Capital Outperform
2016-02-09 Downgrade JP Morgan Overweight → Neutral
2016-02-09 Downgrade Needham Buy → Hold
Mostra tutto

Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie

pulisher
Aug 07, 2025

BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st

Aug 07, 2025
pulisher
Aug 06, 2025

BioCryst Pharmaceuticals 2025 Q2 Earnings Record Net Income Surges 140% - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 06, 2025
pulisher
Aug 06, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Aug 06, 2025
pulisher
Aug 06, 2025

BioCryst Awards Massive Stock Package: 10 New Hires Get 126,450 Shares in Options and RSUs - Stock Titan

Aug 06, 2025
pulisher
Aug 05, 2025

BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

BioCryst (BCRX) Q2 Revenue Jumps 50% - AOL.com

Aug 05, 2025
pulisher
Aug 05, 2025

BioCryst Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

BioCryst: Q2 Earnings Snapshot - New Haven Register

Aug 05, 2025
pulisher
Aug 05, 2025

BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

BioCryst Pharmaceuticals Reports Record Q2 2025 Results - TipRanks

Aug 05, 2025
pulisher
Aug 04, 2025

BioCryst Pharmaceuticals: A Strategic Blueprint for $1 Billion in ORLADEYO Revenue by 2027 - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Pharmaceuticals' Q2 2025: Unpacking Contradictions in ORLADEYO Demand, Market Share, and Financial Metrics - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level - Stocktwits

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Pharmaceuticals Soars 15.35% on Strong Earnings - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Earnings call transcript: BioCryst Q2 2025 sees strong earnings beat, shares surge - Investing.com

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Pharmaceuticals Reports Impressive Q2 EarningsNews and Statistics - IndexBox

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Keeps Momentum With Strong ORLADEYO Sales And Rising Profits - Finimize

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Pharma soars 6.4% as Q2 results crush expectations - Investing.com

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates By Investing.com - Investing.com Canada

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Pharmaceuticals: A High-Conviction Biotech Play with a Defensible Moat in Rare Disease Innovation - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Reports Strong Q2 2025 Financial Performance - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

Is This the Dip to Buy in BioCryst Pharmaceuticals Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst (BCRX) Q2 Revenue Jumps 50% - The Motley Fool

Aug 04, 2025
pulisher
Aug 04, 2025

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Aug 04, 2025
pulisher
Aug 03, 2025

Is it the right time to buy BioCryst Pharmaceuticals Inc. stockTrack high-yield stocks before they peak - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of BioCryst Pharmaceuticals Inc. stockDiscover undervalued stocks before they soar - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastTrack top-performing stocks effortlessly - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How strong is BioCryst Pharmaceuticals Inc. company’s balance sheetCapitalize on emerging industry trends - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes BioCryst Pharmaceuticals Inc. stock price move sharplyMaximize gains with expert analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does BioCryst Pharmaceuticals Inc. compare to its industry peersDiscover breakthrough stocks before the crowd - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is BioCryst Pharmaceuticals Inc. a growth stock or a value stockInvest confidently with professional market insights - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is BioCryst Pharmaceuticals Inc. stock expected to show significant growthStrong return on investment - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

How volatile is BioCryst Pharmaceuticals Inc. stock compared to the marketBuild wealth steadily with smart stock selection - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What catalysts could drive BioCryst Pharmaceuticals Inc. stock higher in 2025Unlock expert stock analysis and alerts - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What are the technical indicators suggesting about BioCryst Pharmaceuticals Inc.Double or triple returns - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN

Aug 02, 2025
pulisher
Aug 02, 2025

Is BioCryst Pharmaceuticals Inc. a good long term investmentFree Stock Market Query - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Is BioCryst Pharmaceuticals Inc. stock overvalued or undervaluedFind the best stocks for sustainable growth - Jammu Links News

Aug 02, 2025
pulisher
Aug 01, 2025

BioCryst Pharmaceuticals Q2 2025 Earnings Preview: Revenue Expected to Rise 37% YoY - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

BioCryst Announces New President Amid Leadership Change - The Globe and Mail

Aug 01, 2025
pulisher
Jul 31, 2025

Healthcare Triangle, Inc. shares fall 3.23% after-hours as BioCryst Pharmaceuticals announces CEO transition. - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse - GlobeNewswire

Jul 31, 2025
pulisher
Jul 31, 2025

BioCryst Pharmaceuticals' Leadership Transition: Strategic CEO Appointment and Its Impact on Pipeline Execution and Shareholder Value Creation - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

BioCryst Pharmaceuticals Before Q2 Earnings: How To Play The Stock - Barchart.com

Jul 31, 2025
pulisher
Jul 31, 2025

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock - The Globe and Mail

Jul 31, 2025

Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$26.60
price up icon 0.09%
$16.38
price down icon 0.77%
$9.435
price up icon 0.59%
drug_manufacturers_specialty_generic RDY
$13.69
price up icon 0.57%
$124.56
price down icon 0.90%
$301.80
price up icon 0.80%
Capitalizzazione:     |  Volume (24 ore):